Literature DB >> 19250221

Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth.

Antonella Cusimano1, Daniela Foderà, Nadia Lampiasi, Antonina Azzolina, Monica Notarbartolo, Lydia Giannitrapani, Natale D'Alessandro, Giuseppe Montalto, Melchiorre Cervello.   

Abstract

The aim of this study was to investigate the expression of prostaglandin E(2) receptors (EP(1-4)), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP(1) receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP(1-4), COX-1, and COX-2 mRNA expression was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP(1) receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-dependent manner. Moreover, treatment with the combination of EP(1) receptor antagonist and COX inhibitors produced a significantly greater cell growth inhibition than the single agent alone. These findings suggest that the EP(1) receptor may represent an important target for HCC treatment, and in addition they could provide preclinical support for a combined chemotherapeutic approach with EP(1) antagonists and COX inhibitors in the treatment of liver cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250221     DOI: 10.1111/j.1749-6632.2009.03701.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

Review 1.  COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models?

Authors:  Paloma Martín-Sanz; Rafael Mayoral; Marta Casado; Lisardo Boscá
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

2.  Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.

Authors:  Cristina Llorente Izquierdo; Rafael Mayoral; Juana María Flores; Pilar García-Palencia; Carme Cucarella; Lisardo Boscá; Marta Casado; Paloma Martín-Sanz
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

3.  Regulation of MicroRNA 183 by Cyclooxygenase 2 in Liver Is DEAD-Box Helicase p68 (DDX5) Dependent: Role in Insulin Signaling.

Authors:  Omar Motiño; Daniel E Francés; Rafael Mayoral; Luis Castro-Sánchez; María Fernández-Velasco; Lisardo Boscá; Carmelo García-Monzón; Rocío Brea; Marta Casado; Noelia Agra; Paloma Martín-Sanz
Journal:  Mol Cell Biol       Date:  2015-05-11       Impact factor: 4.272

4.  Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.

Authors:  Juan Jin; Yan Chang; Wei Wei; Yi-fu He; Shan-shan Hu; Di Wang; Yu-jing Wu
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

5.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012

6.  Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival.

Authors:  Hao-Jie Yang; Jing-Hang Jiang; Yu-Ting Yang; Xiang-Di Yang; Zhe Guo; Ya-Peng Qi; Feng-Hua Zeng; Ke-Lan Zhang; Neng-Zhi Chen; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

7.  Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives.

Authors:  Paloma Martín-Sanz; Marta Casado; Lisardo Boscá
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

8.  Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma.

Authors:  A Fernández-Alvarez; C Llorente-Izquierdo; R Mayoral; N Agra; L Boscá; M Casado; P Martín-Sanz
Journal:  Oncogenesis       Date:  2012-07-09       Impact factor: 7.485

9.  Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells.

Authors:  Noelia Agra Andrieu; Omar Motiño; Rafael Mayoral; Cristina Llorente Izquierdo; Ana Fernández-Alvarez; Lisardo Boscá; Marta Casado; Paloma Martín-Sanz
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.

Authors:  Melchiorre Cervello; Dimcho Bachvarov; Nadia Lampiasi; Antonella Cusimano; Antonina Azzolina; James A McCubrey; Giuseppe Montalto
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.